Trailing-twelve-month (TTM) revenue is $68.18 Million with a year-over-year growth of +20.89%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $17,631,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-12 |
| Q4 FY2025Period ended 2025-12-31 | $16,079,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-26 |
| Q1 FY2026Period ended 2026-03-31 | $15,961,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-13 |
| Q2 FY2026Period ended 2026-06-30 | $18,510,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-12 |
| TTM revenue | $68,181,000 |
Current P/S: $169,533,912 market capitalization ÷ $68,181,000 TTM revenue = 2.49x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T20:00:00.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $18.51M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T20:41:10.378Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20182018-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Accutane | N/A | $10M | $18M | $20M | $19M | $13M |
| Amzeeq | N/A | N/A | $7M |
$68.18M
$68.18 Million
+20.89%
vs. $56.40M a year ago (TTM)
+6.75%
5 Year compound annual growth rate
1 Year
+20.89%
3 Year
(5.60%)
5 Year
+6.75%
10 Year
+16.66%
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $61.86M | +$5.72M | +10.20% |
| 2024 | $56.13M | ($23.05M) | (29.11%) |
| 2023 | $79.18M | +$5.51M | +7.48% |
| 2022 | $73.67M | +$10.54M | +16.69% |
| 2021 | $63.13M | +$18.60M | +41.78% |
| 2020 |
TTM Growth
+20.89%
3-Year CAGR
(5.60%)
5-Year CAGR
+6.75%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 27 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T20:41:10.378Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| $5M |
| N/A |
| Exelderm | N/A | $5M | $3M | $2M | N/A | N/A |
|---|
| Other Branded Products | N/A | $37,000 | N/A | N/A | N/A | N/A |
|---|
| Product | $3M | N/A | N/A | N/A | N/A | N/A |
|---|
| Qbrexa | N/A | $17M | N/A | N/A | N/A | N/A |
|---|
| Qbrexza | N/A | N/A | $27M | $25M | $25M | $25M |
|---|
| Targadox | N/A | $22M | $8M | $3M | N/A | N/A |
|---|
| Ximino | N/A | $8M | $5M | $287,000 | N/A | N/A |
|---|
| Zilxi | N/A | N/A | $2M | $2M | $2M | N/A |
|---|
| $44.53M |
| +$9.61M |
| +27.52% |
| 2019 | $34.92M | ($7.42M) | (17.52%) |
| 2018 | $42.34M | +$37.80M | +832.37% |
| 2017 | $4.54M | ($18.04M) | (79.89%) |
| 2016 | $22.59M | +$15.29M | +209.38% |
